Finally, new IL-1-inhibiting agents, including canakinumab, gevokizumab, and rilonacept, which are not associated with the discomfort of daily injection, already showed some efficacy in RA and T2D [6,36,46,48–50]. Here, IL1B is linked to rheumatoid arthritis.